Review



human m6a-mrna&lncrna epitranscriptomic microarray  (Arraystar inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Arraystar inc human m6a-mrna&lncrna epitranscriptomic microarray
    Human M6a Mrna&Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/human+mrna+lncrna+epitranscriptomic+microarray/pm38945353-82-14-22
    Average 90 stars, based on 1 article reviews
    human m6a-mrna&lncrna epitranscriptomic microarray - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Extraction:

    Article Title: RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia.
    Article Snippet: Samples were sequenced at an average depth of 15.6 million unique reads per sample. m6A array Human spinal cord samples were homogenized in Trizol and RNA was extracted using phenol-chloroform extraction for the m6A mRNA & lncRNA Epitranscriptomic microarray (8x60K, Arraystar, Rockville, MD, USA).

    Microarray:

    Article Title: RNA methylation influences TDP43 binding and disease pathogenesis in models of amyotrophic lateral sclerosis and frontotemporal dementia.
    Article Snippet: Samples were sequenced at an average depth of 15.6 million unique reads per sample. m6A array Human spinal cord samples were homogenized in Trizol and RNA was extracted using phenol-chloroform extraction for the m6A mRNA & lncRNA Epitranscriptomic microarray (8x60K, Arraystar, Rockville, MD, USA).



    Similar Products

    exosome delivered mettl14 ↑ m6a at nfatc1 4249a mrna decay  (Exosome Diagnostics)
    86
    Exosome Diagnostics exosome delivered mettl14 ↑ m6a at nfatc1 4249a mrna decay
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    Exosome Delivered Mettl14 ↑ M6a At Nfatc1 4249a Mrna Decay, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/delivered+drives+enzyme+exosome+glycolysis+hypoxia+induced+mettl14/pmc12634355-14-14-14
    Average 86 stars, based on 1 article reviews
    exosome delivered mettl14 ↑ m6a at nfatc1 4249a mrna decay - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    epiquik mrna m6a methylation quantification kit  (EpiGentek)
    90
    EpiGentek epiquik mrna m6a methylation quantification kit
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    Epiquik Mrna M6a Methylation Quantification Kit, supplied by EpiGentek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/epiquik+m6a+rna+methylation+quantification+kit/pm39858193-66-8-14
    Average 90 stars, based on 1 article reviews
    epiquik mrna m6a methylation quantification kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human m6a-mrna&lncrna epitranscriptomic microarray  (Arraystar inc)
    90
    Arraystar inc human m6a-mrna&lncrna epitranscriptomic microarray
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    Human M6a Mrna&Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/human+mrna+lncrna+epitranscriptomic+microarray/pm38945353-82-14-22
    Average 90 stars, based on 1 article reviews
    human m6a-mrna&lncrna epitranscriptomic microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    epiquik m6a/mrna methylation quantification kit  (EpiGentek)
    90
    EpiGentek epiquik m6a/mrna methylation quantification kit
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    Epiquik M6a/Mrna Methylation Quantification Kit, supplied by EpiGentek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/epiquik+m6a+rna+methylation+quantification+kit/pmc11268744-68-10-15
    Average 90 stars, based on 1 article reviews
    epiquik m6a/mrna methylation quantification kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    m6a mrna epitranscriptomic array  (Arraystar inc)
    90
    Arraystar inc m6a mrna epitranscriptomic array
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    M6a Mrna Epitranscriptomic Array, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/m6a+circrna+epitranscriptomic+microarray/pm38367942-75-1-10
    Average 90 stars, based on 1 article reviews
    m6a mrna epitranscriptomic array - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    m6a-mrna&lncrna epitranscriptomic microarray  (Arraystar inc)
    90
    Arraystar inc m6a-mrna&lncrna epitranscriptomic microarray
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    M6a Mrna&Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/human+mrna+lncrna+epitranscriptomic+microarray/pm38142659-89-15-18
    Average 90 stars, based on 1 article reviews
    m6a-mrna&lncrna epitranscriptomic microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    slit2 m6a-methylated mrna  (SLIT2 LTD)
    90
    SLIT2 LTD slit2 m6a-methylated mrna
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    Slit2 M6a Methylated Mrna, supplied by SLIT2 LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/recombinant+slit2/pm37861451-223-6-5
    Average 90 stars, based on 1 article reviews
    slit2 m6a-methylated mrna - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    m6a mrna immunoprecipitation sequencing (merip-seq)  (CloudSeq Biotech Inc)
    90
    CloudSeq Biotech Inc m6a mrna immunoprecipitation sequencing (merip-seq)
    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and <t>NFATc1,</t> as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.
    M6a Mrna Immunoprecipitation Sequencing (Merip Seq), supplied by CloudSeq Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/m6a+ip+seq+service/pm37963393-47-1-9
    Average 90 stars, based on 1 article reviews
    m6a mrna immunoprecipitation sequencing (merip-seq) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human m6a-mrna and lncrna epitranscriptomic microarray  (Arraystar inc)
    90
    Arraystar inc human m6a-mrna and lncrna epitranscriptomic microarray
    Primer sequences for key <t> LncRNA </t> and GAPDH.
    Human M6a Mrna And Lncrna Epitranscriptomic Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/human+mrna+lncrna+epitranscriptomic+microarray/pmc11470819-53-19-22
    Average 90 stars, based on 1 article reviews
    human m6a-mrna and lncrna epitranscriptomic microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mrna m6a sequencing  (Novogene)
    90
    Novogene mrna m6a sequencing
    Primer sequences for key <t> LncRNA </t> and GAPDH.
    Mrna M6a Sequencing, supplied by Novogene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/m6a+mrna+%26+lncrna+epitranscriptomic+microarray+(8x60k)/m6a+seq/pm37648253-355-32-39
    Average 90 stars, based on 1 article reviews
    mrna m6a sequencing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and NFATc1, as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.

    Journal: Frontiers in Pharmacology

    Article Title: DNA methylation and immune regulation in osteoporosis: emerging epigenetic targets for drug discovery

    doi: 10.3389/fphar.2025.1688305

    Figure Lengend Snippet: The Triad of Osteoporosis: Pathophysiology, Molecular Pathways, and Treatment Approaches. From healthy bones to the development of osteoporosis. It integrates various factors: aging, hormonal abnormalities, inflammation, etc. It involves multi-layered mechanisms: from immune-bone interaction regulation to epigenetic regulation mediated by DNA methylation, analyzing the molecular mechanisms of bone metabolism disorders. Specifically, DNA methylation mediated by DNMT1/3A/3B exerts dual regulatory effects: on one hand, it targets and modulates key bone metabolism-related genes such as Runx2, SOST, and NFATc1, as well as signaling pathways including RANKL/RANK and Wnt/β-Catenin; on the other hand, it influences immune-osseous signaling pathways involving M1/M2 macrophages, T cells, IL-1RN, and NF-κB. Both regulatory effects ultimately drive the imbalance between bone resorption and bone formation. It covers multiple therapeutic strategies: various existing treatments, the potential use of DNMTi. And correlates bone turnover markers (BTM) with the diagnostic value of DNA methylation biomarkers.

    Article Snippet: (Cell Death Dis) , Mouse and human cells , NFATc1 (RNA m6A; METTL14/YTHDF2) , Exosome-delivered METTL14 ↑ m6A at NFATc1 (4249A) → mRNA decay , Inhibits osteoclast resorption, preserves bone , .

    Techniques: DNA Methylation Assay, Protein-Protein interactions, Diagnostic Assay

    Primer sequences for key LncRNA and GAPDH.

    Journal: International Journal of Genomics

    Article Title: M6A Modification and Transcription Analysis of LncRNA in Cerebral Ischemia/Reperfusion Injury

    doi: 10.1155/2024/4596974

    Figure Lengend Snippet: Primer sequences for key LncRNA and GAPDH.

    Article Snippet: On the one hand, the m6A modification level of LncRNA in samples was detected with Arraystar human m6A-mRNA and lncRNA epitranscriptomic microarray (Arraystar) according to the instruction manual [ ].

    Techniques: Sequencing

    Network of LncRNA-miRNA-mRNA was constructed to demonstrate possible regulatory relationships among lncRNAs, miRNAs, and mRNAs (the top 10 most significant target genes). Red represents LncRNAs, blue represents miRNAs, and green represents mRNAs.

    Journal: International Journal of Genomics

    Article Title: M6A Modification and Transcription Analysis of LncRNA in Cerebral Ischemia/Reperfusion Injury

    doi: 10.1155/2024/4596974

    Figure Lengend Snippet: Network of LncRNA-miRNA-mRNA was constructed to demonstrate possible regulatory relationships among lncRNAs, miRNAs, and mRNAs (the top 10 most significant target genes). Red represents LncRNAs, blue represents miRNAs, and green represents mRNAs.

    Article Snippet: On the one hand, the m6A modification level of LncRNA in samples was detected with Arraystar human m6A-mRNA and lncRNA epitranscriptomic microarray (Arraystar) according to the instruction manual [ ].

    Techniques: Construct

    The expression levels of the four key LncRNAs in the 12 pairs of blood were quantified using qRT-PCR. Comparing with the control group, the expression levels of LncRNA FAR2, LncRNA LINC02431, and LncRNA AL357060.1 were downregulated, while the expression level of LncRNA FOXD2-AS1 was upregulated. ∗∗∗∗ p < 0.0001.

    Journal: International Journal of Genomics

    Article Title: M6A Modification and Transcription Analysis of LncRNA in Cerebral Ischemia/Reperfusion Injury

    doi: 10.1155/2024/4596974

    Figure Lengend Snippet: The expression levels of the four key LncRNAs in the 12 pairs of blood were quantified using qRT-PCR. Comparing with the control group, the expression levels of LncRNA FAR2, LncRNA LINC02431, and LncRNA AL357060.1 were downregulated, while the expression level of LncRNA FOXD2-AS1 was upregulated. ∗∗∗∗ p < 0.0001.

    Article Snippet: On the one hand, the m6A modification level of LncRNA in samples was detected with Arraystar human m6A-mRNA and lncRNA epitranscriptomic microarray (Arraystar) according to the instruction manual [ ].

    Techniques: Expressing, Quantitative RT-PCR, Control

    The methylation levels of the four key LncRNAs in the 12 pairs of blood were quantified using MeRip-qPCR. Comparing with control group, the methylation levels of LncRNA FAR2, LncRNA FOXD2-AS1, and LncRNA AL357060.1 were hypomethylated, while the methylation level of LncRNA LINC02431 was not significantly different. ∗∗∗∗ p < 0.0001. ns: nonsignificant.

    Journal: International Journal of Genomics

    Article Title: M6A Modification and Transcription Analysis of LncRNA in Cerebral Ischemia/Reperfusion Injury

    doi: 10.1155/2024/4596974

    Figure Lengend Snippet: The methylation levels of the four key LncRNAs in the 12 pairs of blood were quantified using MeRip-qPCR. Comparing with control group, the methylation levels of LncRNA FAR2, LncRNA FOXD2-AS1, and LncRNA AL357060.1 were hypomethylated, while the methylation level of LncRNA LINC02431 was not significantly different. ∗∗∗∗ p < 0.0001. ns: nonsignificant.

    Article Snippet: On the one hand, the m6A modification level of LncRNA in samples was detected with Arraystar human m6A-mRNA and lncRNA epitranscriptomic microarray (Arraystar) according to the instruction manual [ ].

    Techniques: Methylation, Control